Campbell & Co Investment Adviser’s Vanda Pharmaceuticals VNDA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-24,641	Closed	-$139K	–	1361
2024 Q2	$139K	Sell	24,641 -44,042	-64%	-$227K	0.01%	988
2024 Q1	$282K	Buy	68,683 +30,661	+81%	+$123K	0.02%	929
2023 Q4	$160K	Buy	38,022 +12,186	+47%	+$49.2K	0.01%	1043
2023 Q3	$112K	Sell	25,836 -19,175	-43%	-$107K	0.01%	894
2023 Q2	$297K	Buy	+45,011	New	+$289K	0.05%	670
2022 Q3	–	Sell	-11,803	Closed	-$129K	–	958
2022 Q2	$129K	Buy	11,803 +1,303	+12%	+$13.5K	0.03%	636
2022 Q1	$119K	Buy	+10,500	New	+$138K	0.03%	660
2021 Q2	–	Sell	-12,100	Closed	-$182K	–	730
2021 Q1	$182K	Buy	+12,100	New	+$196K	0.11%	369
2020 Q1	–	Sell	-15,137	Closed	-$248K	–	515
2019 Q4	$248K	Buy	+15,137	New	+$229K	0.08%	502

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Campbell & Co Investment Adviser's VNDA Position: Q3 2024 in Review

Campbell & Co Investment Adviser sold out of Vanda Pharmaceuticals (VNDA) in Q3 2024, closing a stake of 24,641 shares — an estimated $139K sold.

Campbell & Co Investment Adviser first reported a position in VNDA in Q4 2019 and held it in 9 quarters. The position peaked at $297K in Q2 2023. 152 funds tracked by Wall St. Rank hold VNDA as of Q3 2024.

Campbell & Co Investment Adviser reported no remaining Vanda Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Campbell & Co Investment Adviser sold 24,641 Vanda Pharmaceuticals shares in Q3 2024, an estimated $139K.
Campbell & Co Investment Adviser first reported a position in Vanda Pharmaceuticals in Q4 2019 and held it in 9 quarters.
Campbell & Co Investment Adviser's Vanda Pharmaceuticals position peaked at $297K in Q2 2023.
152 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2024, filed 12 Nov 2024.